Carvolix has raised an additional €10 million tranche, bringing total funding under its €30 million financing programme to €20 million. The new capital reflects continued support from existing strategic shareholders and is intended to support both commercialization and clinical development of its AI-driven cardiovascular and neurovascular technologies.
The company will allocate proceeds primarily to its pipeline, including Tavipilot (30%), Kalios (23%), Artus (21%), Artedrone (19%), and Mitrapilot (7%), while also repaying a bridge loan.
Related: Tissium closes $68M financing for tissue reconstruction polymers
Carvolix CEO Sébastien Ladet said:
“The renewed commitment from our long-standing shareholders demonstrates their confidence in our roadmap and the innovative nature of our AI-driven robotic platforms.”
The funds will support key milestones including U.S. commercialization of Tavipilot, FDA submissions, ongoing clinical studies, and preclinical development across its robotic and implant-based cardiovascular technologies.
The company estimates current cash will fund operations until end of September 2026, while it is negotiating a €25 million venture debt facility to extend its runway beyond 12 months. Additional financing discussions and non-dilutive funding options are also underway.
Upcoming catalysts include FDA submissions and clearance milestones for Tavipilot in late 2026, alongside clinical updates for multiple pipeline programs.
Overall, the financing strengthens Carvolix’s ability to advance its AI-enabled interventional platforms toward regulatory approval and early commercialization, while still relying on additional funding to fully support its longer-term development plan.
